Clinical Trial

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 28, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-26; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07206758
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Immune Thrombocytopenia
Enrollment 10 participants
Start Date 2025-11-12
Primary Completion 2026-06 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-28